average weight loss on retatrutide VisualAbstract: reduces body by 17.5% in patients with obesity A Clinician's Guide to Retatrutide

It's a process of persuasion, not brute force

Neurogastrx is studying investigational metopimazine to reduce the incidence, duration and severity of nausea and vomiting associated with GLP-1s

Expanded obesity drug coverage can increase Medicaid spending and put pressure on overall state budgets, and states are now facing tighter budget conditions and longer-term fiscal uncertainty, due in part to the federal Medicaid cuts in the 2025 reconciliation law, causing state Medicaid programs to re-evaluate their obesity drug coverage

(Removed: "Therapeutic Role in Brain Disorders") Drge W, Breitkreutz R

Since patients in the study population with obesity were for the first time prescribed semaglutide after 6/2021, there was no overlap in the exposure cohorts for these two study populations